

Quality of life in heart failure. The heart of the matter. A scientific statement of the Heart Failure Association and the European Association of Preventive Cardiology of the European Society of Cardiology

Maurizio Volterrani^{1,2}, Geza Halasz ³, Stamatis Adamopoulos⁴, Pier Giuseppe Agostoni^{5,6}, Javed Butler^{7,8}, Andrew JS. Coats⁹, Alan Cohen-Solal ¹⁰, Wolfram Doehner ^{11,12,13}, Gerasimos Filippatos¹⁴, Ewa Jankowska¹⁵, Carolyn S.P. Lam^{16,17}, Ekaterini Lambrinou ¹⁸, Lars H. Lund^{19,20,21}, Giuseppe Rosano ²², Marco Metra ²³, Stefania Paolillo²⁴, Pasquale Perrone Filardi²⁴, Amina Rakisheva²⁵, Gianluigi Savarese¹⁹, Petar Seferovic^{26,27}, Carlo Gabriele Tocchetti²⁸, and Massimo Piepoli^{29,30*}

¹IRCCS San Raffaele Roma, 00166 Rome, Italy; ²San Raffaele Open University in Rome, Italy; ³Azienda Ospedaliera San Camillo-Forlanini, Rome, Italy; ⁴Onassion Hospital, Athens, Greece; ⁵Centro Cardiologico Monzino, IRCCS, Milan, Italy; ⁶Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy; ⁷Baylor Scott and White Research Institute, Dallas, TX; ⁸Department of Medicine, University of Mississippi, Jackson, MS, USA; ⁹Heart Research Institute, Sydney, Australia; ¹⁰Universite Paris Cité, France; ¹¹Berlin Institute of Health Center for Regenerative Therapies, Charité—Universitätsmedizin Berlin, Berlin, Germany; ¹²Center for Stroke Research Berlin and German Centre for Cardiovascular Research (DZHK), partner site Berlin, Berlin, Germany; ¹³Deutsches Herzzentrum der Charité, Department of Cardiology (Campus Virchow), Charité Universitätsmedizin Berlin; ¹⁴Department of Cardiology, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens, Greece; ¹⁵University of Wrocław, Poland; ¹⁶National Heart Centre Singapore, Singapore; ¹⁷Duke-National University of Singapore, Singapore; ¹⁸Cyprus University of Technology, Cyprus; ¹⁹Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; ²⁰Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden; ²¹Heart and Vascular Theme, Karolinska University Hospital, Stockholm, Sweden; ²²San Raffaele Cassino Hospital, Cassino, Italy; ²³Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy; ²⁴Department of Advanced Biomedical Sciences, Federico II University, Naples, Italy; ²⁵Cardiology Department, Scientific Institute of Cardiology and Internal Medicine, Almaty, Kazakhstan; ²⁶University Faculty of Medicine, University of Belgrade, Belgrade, Serbia; ²⁷Serbian Academy of Arts and Sciences, Belgrade, Serbia; ²⁸Department of Translational Medical Sciences (DISMET), Center for Basic and Clinical Immunology Research (CISI), Interdepartmental Center for Clinical and Translational Research (CIRCET), Interdepartmental Hypertension Research Center (CIRIAPA), Federico II University, Naples, Italy; ²⁹Clinical Cardiology, IRCCS Policlinico San Donato, San Donato Milanese, Via Morandi 30, Milan 20097, Italy; and ³⁰Department of Biomedical Science for Health, University of Milan, Via Festa del Perdono, Milan 20100, Italy

Received 23 January 2023; revised 2 December 2023; accepted 5 December 2023; online publish-ahead-of-print 12 March 2025

For most patients with chronic, progressive illnesses, maintaining good quality of life (QoL), with preserved functional capacity, is just as crucial as prolonging survival. Patients with heart failure (HF) experience much worse QoL and effort intolerance than both the general population and people with other chronic conditions, since they present a range of physical and psychological symptoms, including shortness of breath, chest discomfort, fatigue, fluid congestion, trouble with sleeping, and depression. These symptoms reduce patients' capacity for daily social and physical activity. Usual endpoints of large-scale trials in chronic HF have mostly been defined to evaluate treatments regarding hospitalizations and mortality, but more recently, patients' priorities and needs expressed with QoL are gaining more awareness and are being more extensively evaluated. This scientific statement aims at discussing the importance of QoL in HF, summarizing the most largely adopted questionnaires in HF care, and providing an overview on their application in trials and the potential for their transition to clinical practice. Finally, by discussing the reasons limiting their application in daily clinical routine and the strategies that may promote their implementation, this statement aims at fostering the systematic integration of the patient's standpoint in HF care.

Keywords

Aging • Chronic disease • Exercise tolerance • Functional capacity • Frailty • Heart failure • Physical activity • Quality of life

* Corresponding author. Tel: +390 2 52774 966, Fax: +390 2 5274717, Email: massimo.piepoli@unimi.it

This article has been co-published with permission in the *European Journal of Preventive Cardiology* and *European Journal of Heart Failure*. All rights reserved. © the European Society of Cardiology 2025. The articles are identical except for minor stylistic and spelling differences in keeping with each journal's style. Either citation can be used when citing this article.

Introduction

Maintaining a high quality of life (QoL) for the majority of patients with progressive, chronic illnesses is equally as important as assuring their survival.¹ In particular, patients with heart failure (HF) tend to have a lower QoL and more exercise intolerance than subjects with chronic conditions: they experience a variety of physical and psychological symptoms, including dyspnoea, chest discomfort, fatigue, oedema, difficulty with sleeping, and depression.^{2,3}

In the Echocardiographic Heart of England Screening (ECHOES) study, enrolling 6162 people in the community screened with echocardiographic assessment in England and estimating the prevalence of left ventricular systolic dysfunction, patients with HF had significant impairment of all measured aspects of physical and mental health together with reduced physical function, as measured through the health status questionnaire, with significantly worse impairment with more severe New York Heart Association (NYHA) functional class.⁴

Furthermore, in more than 1 million hospital cases in Sweden between 1988 and 2004, the impact of HF on QoL was higher than other disabling conditions, such as prostate, colorectal, lung, and bladder cancer.⁵ These symptoms make it harder for patients to engage in daily social and physical activity. Moreover, the progression and prognosis in HF are unpredictable, which may also have a negative impact on patients' QoL.⁶

Numerous studies have shown that QoL plays a part in predicting both the utilization of healthcare services and mortality.³

The importance of QoL for patients with HF is highlighted in a survey showing that 61% attached more weight to QoL over longevity, with 9% and 14% willing to trade 6 and 12 months, respectively, for perfect health and better QoL.⁷

The crucial role of patient-reported outcome (PRO) questionnaires has been recently underlined and their role in shared clinical decision-making, quality monitoring and improvement, clinical trials, regulatory and reimbursement decisions, and the digital health arena revised.⁸

This scientific statement of the Heart Failure Association and the European Association of Preventive Cardiology of the European Society of Cardiology (ESC) aims at discussing the importance QoL in HF, summarizing the most largely adopted questionnaires, and providing an overview on their application in trials and the potential for their transition to clinical practice. By discussing the reasons limiting their application in daily clinical routine and the strategies that may promote their implementation, this statement aims at fostering the systematic integration of the patient's standpoint in HF care.

Definitions and assessment of quality of life in heart failure patients

The definition and assessment of QoL are poorly described. The terms QoL and health-related QoL (HRQoL) are frequently used interchangeably, and some definitions fail to differentiate between the two.

In fact, it is difficult to conceive of significant aspects of QoL that are not at least partially influenced by health, especially when indirect effects are taken into account (e.g. health influences income and, consequently, housing, education).⁹

However, apart from the definitions used, the concept of QoL is subjective and multidimensional, encompassing physical and occupational function, psychological state, social interaction, and somatic sensation.¹⁰

In this document, the definition of QoL includes three components: (i) the ability to carry out activities (physical and social), (ii) the ability to maintain happiness, and (iii) the ability to engage in fulfilling relationships with others. All these components are influenced by important factors, such as social factors, general health status, economic status, self-care behaviour, and psychological factors (Figure 1).

Several QoL questionnaires have been used in HF, some of these are disease-specific for HF, and others are non-disease-specific. Several reasons have limited their implementation such as the lack of a clear role as prognosticator, the limited coverage of symptom expression, limited feasibility and interpretability, language barriers, content validity, and the limited availability of validation studies. Table 1 summarizes the most common questionnaires, classified in HF disease-specific and non-disease-specific, highlighting the specific domains measured, country and year of development, score range, and modality of administration.

Disease-specific questionnaires

Among the disease-specific questionnaires, the Minnesota Living with Heart Failure Questionnaire (MLHFQ) and the Kansas City Cardiomyopathy Questionnaire (KCCQ) have been qualified as Medical Device Development Tools by the Food and Drug Administration (FDA) Center for Devices and Radiological Health, with KCCQ also qualifying as Clinical Outcome Assessment by the FDA Center for Drug Evaluation and Research for cardiovascular trials.^{21,22}

The KCCQ includes 23 items that capture the impact of HF on 7 different domains within a 2-week recall period. These domains include symptom frequency, stability, and burden, as well as physical and social limitations, QoL, and self-efficacy (i.e. the patients' understanding of their HF management).¹¹

To increase the feasibility of its use, its 23 items (KCCQ-23) were reduced to 12 items, while maintaining the reliability, validity, and prognostic properties of the full instrument.²³

Although KCCQ-12 might be the best choice for clinical purposes, the full version is preferred for use in clinical trials because it has been qualified as clinical outcome by the FDA to support labelling.

In a prospective cohort of 476 HF outpatients, KCCQ accurately reflected clinical changes compared with 6-min walking distances (6MWD) and NYHA class, with higher sensitivity in the identification of small clinical deteriorations that were not discriminated by the two other measures.²⁴

The KCCQ and NYHA class provide similar assessment of functional capacity as measured by peak exercise oxygen consumption (pVO_2).²⁵

Changes in KCCQ scores have been shown to correlate with changes in functional capacity, as measured by the 6MWD and cardiopulmonary exercise test. A 5-point overall change in the KCCQ score corresponded to a 1.4 mL/min/kg change in pVO_2 at the cardiopulmonary exercise test and to a 49.7 m change in distance walked at the 6MWD.²⁶

The MLHFQ includes 21 items mapping physical and emotional domains within a 4-week recall period. Eight items are not included in these domains but are considered for the calculation of the total score. The total score ranges between 0 and 105, with lower scores indicating better health status.¹²

Previous data suggest a strong correlation between MLHFQ and exercise capacity measured as 6MWD, particularly in HF with preserved ejection fraction (HFpEF).

Although the MLHFQ has been shown to be associated with pVO_2 , it was not associated with minute ventilation/carbon dioxide production (VE/VCO_2), which is independent of the subject's effort and therefore not influenced by early exercise termination due to symptom perception.²⁷

The MLHFQ has been shown to correlate with NYHA class and to be an independent predictor of mortality/HF hospitalization in both outpatients and inpatients, regardless of left ventricular ejection fraction (LVEF). Comparisons between these two questionnaires are limited.^{28,29}

In HFpEF, MLHFQ and KCCQ were both reliable and valid tools for assessing health-related QoL, but KCCQ was more strongly associated with baseline functional status, whereas MLHFQ was more sensitive in detecting improvements in 6MWD.³⁰

In a combined cohort of HFpEF and HF with reduced ejection fraction (HFrEF), KCCQ was more prognostic of death, transplant, left




Figure 1 Components influencing the quality of life.

ventricular assist device (LVAD), and hospitalization than MLHFQ, suggesting that KCCQ might be the preferred tool if the goal is prognostication.³¹

Notably, improvement in NYHA class was not associated with clinical outcomes, whereas an improvement of ≥ 5 points in KCCQ predicted a 51% lower risk of mortality and a 27% lower risk of mortality/HF hospitalization.³²

The KCCQ and MLHFQ cover many important HF symptoms, with some of them considered by only one of these tools, some others covered by both, and some others not considered by neither (Table 2).

It is important to highlight that it is not questionnaire's aim to evaluate symptoms/signs, but they rather aim to efficiently capture the total burden of HF (in particular chronic symptoms) on the overall patient's health status by taking into consideration several domains, e.g. mental, social, and physical.

Other disease-specific questionnaires are available in HF, including the Chronic Heart Failure Questionnaire (CHFQ), the Quality of Life Questionnaire for Severe Heart Failure (QLQ-SHF), the Left Ventricular Dysfunction Questionnaire (LVDQ), and the Chronic Heart Failure Assessment Tool (CHAT) (Table 1).^{15,16,33,34}

Several reasons have limited their implementation as compared with the more widely adopted KCCQ and MLHFQ which received qualification by the FDA, and among these there are the lack of a clear role as prognosticator, the limited coverage of symptom expression, limited feasibility and interpretability, language barriers, content validity, and the limited availability of validation studies.

Non-disease-specific questionnaires

The information from global clinical assessment derived from non-disease-specific questionnaires provide important additional information.

For example, these questionnaires might be useful for investigating HF interventions when the treatment might also cause major

complications whose impact could be neglected when using disease-specific questionnaires. For example, LVAD improves dyspnoea but might lead to stroke.

The KCCQ or MLHFQ, which focus on HF aspects, might underestimate the impairment of QoL related to the complication, in turn overemphasizing the improvement in HF-related QoL. Global questionnaires such as the EuroQol-5d Questionnaire (EQ-5D) or the Short-Form Health Survey (SF-36) might be particularly useful for the assessment of older patients with multiple chronic diseases, a situation in which HF is not the only contributor to explain patient's health-related QoL, and can facilitate comparisons among patients with different conditions (Table 1).

In particular, EQ-5D has been often used to estimate QoL in HF populations. It assesses five domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. It is commonly used to assess health state utilities, to support cost-effectiveness analyses.³⁵

Application of quality of life questionnaires in clinical practice

The application of QoL questionnaires in HF has been reviewed and divided into settings of pharmacological interventions in HF with reduced (HF_rEF) and preserved (HF_pEF) LVEF (principally assessed by KCCQ and MLHFQ) (Table 3) and non-pharmacological strategies (Table 4).

Pharmacological intervention in heart failure with reduced ejection fraction

In previous studies evaluating guideline-directed medical therapies (GDMT), there is limited evidence of positive effects of pharmacologic

Table 1 Questionnaires to measure quality of life in heart failure

Instrument	Aim: To measure...	Country and year of development	Specific domains	Score range	Mode of administration
Disease-specific questionnaires					
Kansas City Cardiomyopathy Questionnaire (KCCQ) ¹¹	QoL in HF	USA, 1999	<ul style="list-style-type: none"> Physical limitation Symptoms Self-efficacy Social limitation QoL 	0–100 (worst to best)	Self-administered (telephone)
Minnesota Living with Heart Failure Questionnaire (MLHFQ) ¹²	The extent to which HF prevents patients from living the way they would want to	USA, 1987	<ul style="list-style-type: none"> Physical Emotional 	0–105 (best to worst)	Self-administered (telephone)
Cardiac Health Profile congestive heart failure (CHPchf) ¹³	How HF influences subjective perceptions of physical, psychological, and social well-being	Sweden, 2007	<ul style="list-style-type: none"> Symptoms Activity levels Psycho-social emotions 	Visual Analogue Scales	Self-administered
Chronic Heart Failure Questionnaire (CHFQ) ¹⁴	longitudinal change over time within persons with HF	Canada, 1989	<ul style="list-style-type: none"> Dyspnoea Fatigue Emotional 	16–112 (worst to best)	Interview administered (telephone)
Chronic Heart Failure Assessment Tool (CHAT) ¹⁵	QoL from the patient perspective	UK, 2007	<ul style="list-style-type: none"> Symptoms Activity levels Psycho-social Emotions 	A variety of Response scales are used	Self-administered
Left Ventricular Dysfunction Questionnaire (LVD-36) ¹⁶	The impact of left ventricular dysfunction daily life and well-being	UK, 1998	<ul style="list-style-type: none"> Activity levels Psycho-social status 	0–100 (worst to best)	Self-administered (telephone)
Quality of Life Questionnaire in Severe Heart Failure (QLQ-SHF) ¹⁷	Self-assessment of health-related quality of life in severe HF	Sweden, 1987	<ul style="list-style-type: none"> Psychological Physical activity Life dissatisfaction Somatic symptoms 	0–130 (best to worst)	Self-administered
Non-disease-specific questionnaires					
EuroQol five-dimensional questionnaire (EQ-5D) ¹⁸	Generic measure widely used for the assessment of health status	EuroQol Group, 1987	<ul style="list-style-type: none"> Mobility Self-care Usual activities Pain/discomfort Anxiety/depression 	–0.594–1.000 (worst to best)	Self-administered
The MOS 36-item and the Short-Form Health Survey (SF-36 and SF-12) ¹⁹	Multi-item scale to assess health status	Medical Outcomes Study, 1992	<ul style="list-style-type: none"> Physical activities Social activities Usual role Bodily pain Mental health Emotional problems Vitality (energy and fatigue) General health 	0–100 (worst to best)	Self-administered (in person or by phone)
HeartQoL ²⁰	A health-related QoL questionnaire, originally developed in ischaemic heart disease	European Association of Preventive Cardiology, 2014	<ul style="list-style-type: none"> Ten-item physical Four-item emotional 	Each item is scored from 0 to 3 (worst to best)	Self-administered

HF, heart failure; QoL, quality of life.

Table 2 Questionnaire content coverage by Kansas City Cardiomyopathy Questionnaire (KCCQ), Minnesota Living with Heart Failure Questionnaire (MLHFQ), and missing items

KCCQ and MLHFQ	Shortness of breath, fatigue, swelling (oedema) in the feet and ankles, sleeping problems, depression/anxiety, and limitations in working, recreational, and social activities and in intimate/sexual relationship
KCCQ	Exercise limitation, life satisfaction pleasure, and enjoyment of life
MLHFQ	Difficulties in concentrating, eating/drinking disorders, and feeling inadequate, worthless, and a burden to caregivers
Missing items	Swelling in the abdomen; feeling restless and tense; weight gain; lack of appetite, nausea, and chest pain; palpitation and dizziness; and persistent cough or wheezing

interventions using angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, and mineralocorticoid receptor antagonists (MRAs) on exercise capacity and QoL.⁷¹

In a randomized controlled trial involving 1050 African–American patients, the fixed combination of isosorbide dinitrate/hydralazine was associated with improvements in MLHFQ at all times during 18-month follow-up period.

Ivabradine has also been linked to benefits in functional capacity and QoL, although their quantitative clinical relevance is limited.³⁷

Regarding the most recent treatments for HFrEF, the benefit in terms of QoL was demonstrated by all pharmacological intervention. For example, a sub-analysis of the PARADIGM-HF trial conducted on 7623 patients, which completed the KCCQ, reported a significant score improvement in treated patients.³⁹ At 8 months, sacubitril/valsartan improved both KCCQ clinical summary score (CSS) (+0.64 vs. −0.29; $P < 0.01$) and KCCQ overall summary score (KCCQ-OSS) (+1.13 vs. −0.14; $P < 0.001$) compared with enalapril group and significantly less proportion of patients showed a score deterioration (27% vs. 31%; $P = 0.01$). However, 12-week sacubitril/valsartan therapy did not significantly improve functional capacity.^{72,73}

For sodium–glucose cotransporter 2 inhibitor (SGLT2i), an analysis of the DAPA-HF trial investigated the effects of dapagliflozin on QoL, assessed by KCCQ total symptom score (KCCQ-TSS), in 4443 patients at randomization, 4 months, and 8 months.

At 8 months, patients on dapagliflozin showed a greater improvement in mean KCCQ-TSS, KCCQ-CSS, and KCCQ-OSS (respectively 2.8, 2.5, and 2.3 points higher vs. placebo; $P < 0.0001$ for all) and lower rates of score deterioration in KCCQ-TSS [odds ratio (OR) 0.84, 95% confidence interval (CI) 0.78–0.90; $P < 0.0001$].

The effects of dapagliflozin in reducing cardiovascular death or worsening HF were consistent across the range of baseline KCCQ-TSS.⁴⁰

Empagliflozin improved KCCQ-CSS and KCCQ-TSS at 3, 8, and 12 months in the EMPEROR-Reduced trial.⁴¹

Also after an acute event, empagliflozin improved KCCQ-TSS at 15, 30, and 90 days in the EMPULSE trial.⁴³ Only in the small EMPERIAL trial empagliflozin failed to improve significantly QoL.⁵⁰

Collectively, these data consistently demonstrate a beneficial effect of novel HF drugs on health condition, further supporting their use in clinical practice to impact on major cardiovascular outcomes and well-being status.

Pharmacological intervention in heart failure with preserved ejection fraction

Patients with HFpEF tend to be older with multiple comorbidities, in whom reduced exercise tolerance and dyspnoea are key manifestations.⁷⁴ These symptoms, along with frequent hospitalizations, pervade all aspects of daily life, eventually impairing function and independence, two commonly most important limitations in older adults. Indeed, from a trial design perspective, QoL primary endpoints are considered important, as the non-cardiovascular comorbid burden and older age play a major role with respect to prognosis in patients with HFpEF. Patients with HFpEF from PARAGON-HF had lower KCCQ scores in nearly all domains than those with HFrEF from PARADIGM-HF.^{48,75,76}

The 2021 ESC HF guidelines suggest reducing body weight in obese patients, increasing physical activity, and promoting regular exercise for improved QoL.^{77,78}

Several trials have investigated the possibility of pharmacological therapy in improving QoL in patients with HFpEF, with inconsistent results (Table 3).

In the I-PRESERVE trial, irbesartan was unable to change MLHFQ as well as prognostic indicators.⁴⁷

Among the most novel treatment, sacubitril/valsartan showed inconsistent findings. In the PARAGON-HF, the mean change in the KCCQ-CSS at 8 months was higher in the sacubitril/valsartan group compared with the valsartan-alone group.⁴⁸ Yet, results of PARAGON-HF contrast with that of the PARALLAX trial, where, among patients with HF and LVEF > 40%, sacubitril/valsartan treatment did not result in greater improvement of KCCQ-CSS at 24 weeks, despite a greater decrease in plasma N-terminal pro-brain natriuretic peptide levels at 12 weeks.³⁹ Reasons for the lack of improvement in QoL or exercise performance despite the potent biological effect on natriuretic peptides remain unclear.

More consistent positive findings are available for SGLT2i drugs. In particular, dapagliflozin improved QoL, physical limitations, and exercise function in the PRESERVED-HF trial and in pre-specified analysis of the Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure (DELIVER) trial.^{49–51} Patients treated with empagliflozin exhibited a mean KCCQ improvement in the EMPEROR-Preserved trial; this effect manifested early and persisted for a minimum of 1 year, in contrast to the EMPERIAL trial, which failed to observe such a benefit.^{42,52}

The reasons for the discrepant results are unclear but may relate to differences in baseline characteristics (less obese and less likely to be women in EMPERIAL compared with PRESERVED-HF).

Finally, in the abovementioned EMPULSE trial, which included patients with acute HF and LVEF > 40%, initiation of empagliflozin in patients hospitalized for acute HF improved all components of KCCQ, with benefits seen as early as 15 days and maintained through 90 days.⁴³

Regarding MRA drug, spironolactone treatment led to improvement in KCCQ in the TOPCAT trial.⁵³

However, there was no change in generic EQ-5D scale or McMaster Overall Treatment Evaluation, suggesting that non-HF-related QoL was not influenced. TOPCAT also showed that older age, obesity, current smoking habit, NYHA III/IV class, and comorbidities were associated with declines in KCCQ in HFpEF.

Notably, trials targeting the nitric oxide-cyclic guanosine monophosphate pathway failed to improve exercise capacity or QoL in HFpEF, e.g. NEAT-HFpEF, INDIE-HFpEF, VITALITY-HFpEF, and CAPACITY-HF.^{54–57} It is worthwhile to observe that these latter studies presented limited sized study populations which may have played a role.

In conclusion, improving QoL is a key therapy target for HFpEF patients, who value autonomy and activity. There is evidence that some GDMT (in particular sacubitril/valsartan, SGLT2i, and MRA) may improve patient-reported clinical outcomes, but further studies are needed.

Table 3 Pharmacological interventions on heart failure affecting quality of life

Study	Study population	Characteristics of the study population	Tool to measure QoL	Results	
Heart failure with reduced ejection fraction					
Isosorbide dinitrate/hydralazine	A-HeFT ³⁶	1050 African-American	60% male; 56 ± 13 years, 24% LVEF	MLHFQ every 3 months till 18 months	Improvements at all times by average of 3.6 points (<i>P</i> < 0.001)
Ivabradine	APULIA study ³⁷	221: 110 ivabradine; 111 β-blockers	49% male; 64 ± 6 years, 44% LVEF	SF-36 (at baseline and 1 month)	Improvements of physical functioning, physical role functioning, emotional role functioning, and mental health scales vs. β-blockers (<i>P</i> < 0.001)
	SHIFT ³⁸	1944 patients: 968 ivabradine, 976 placebo	76% male; 60 ± 11 years, 28% LVEF	KCCQ at randomization and 4, 8, and 12 months	Improvements in KCCQ by 2.4 OSS and by 1.8 CSS vs. placebo (<i>P</i> < 0.05)
Sacubitril/valsartan	PARADIGM-HF (sub-analysis) ³⁹	7623	79% male; 64 ± 11 years, 30% LVEF	KCCQ at randomization, 4 months, 8 months, and annual visits	At 8 months, sacubitril/valsartan group improved both KCCQ-CSS (+0.64 vs. -0.29; <i>P</i> = 0.008) and KCCQ-OSS (+1.13 vs. -0.14; <i>P</i> < 0.001) vs. enalapril
Dapagliflozin	DAPA-HF (sub-analysis) ⁴⁰	4443	77% male; 66 ± 10 years, 31% LVEF	KCCQ at randomization and 4 and 8 months	Dapagliflozin improved mean KCCQ-TSS, KCCQ-CSS, and KCCQ-OSS at 8 months (2.8, 2.5, and 2.3 points higher vs. placebo; <i>P</i> < 0.0001 for all)
Empagliflozin	EMPEROR-Reduced (sub-analysis) ⁴¹	3705	76% male; 67 years, 27% LVEF	KCCQ at baseline and 3, 8, and 12 months	Empagliflozin improved KCCQ-CSS, KCCQ-OSS, and KCCQ-TSS at 3, 8, and 12 months (<i>P</i> < 0.01)
	EMPERIAL Reduced ⁴²	312	75% male; 69 ± 10 years, 30% LVEF	KCCQ-TSS score at baseline and Week 12	Empagliflozin did not significantly improve KCCQ-TSS
	EMPULSE (sub-analysis) ⁴³	530 hospitalized for acute HF	66% male; 68 ± 13 years, 31% LVEF	KCCQ at baseline and 15, 30, and 90 days	At 90 days improvement in KCCQ-TSS: (+4.5 points) for the empagliflozin group vs. placebo (<i>P</i> = 0.035)
Sotagliflozin	SOLOIST-WHF ⁴⁴	1222 with diabetes	71% male; 69 years, 35% LVEF	KCCQ at 4 months	Sotagliflozin improved KCCQ-CSS (+4.1, <i>P</i> < 0.05)
Ferric carboxymaltose	FAIR-HF ⁴⁵	459	47% male; 67 ± 10 years, 31% LVEF	KCCQ and EQ-5D Visual Analogue Scale at baseline and weeks 4, 12, and 24	KCCQ +7 (<i>P</i> < 0.001) EQ-5D +7 (<i>P</i> < 0.001)
Omecamtiv mecarbil	GALACTIC-HF ⁴⁶	8256	78% male; 64 ± 11 years, 26% LVEF	KCCQ at 24 weeks	No improvements
Heart failure with preserved ejection fraction					
Irbesartan	I-PRESERVE ⁴⁷	3605	39% male; 71 ± 7 years	MLHFQ at randomization and 6, 14, and 56 months	No significant improvement in QoL
Sacubitril/valsartan	PARAGON-HF ⁴⁸	4822	49% male; 72 ± 8 years	KCCQ at randomization and 8 months	Sacubitril/valsartan improved the KCCQ-CSS by five or more points in a higher percentage of patients vs. valsartan (33% vs. 29%; OR 1.3; 95% CI 1.04–1.61)

Continued

Table 3 Continued

	Study	Study population	Characteristics of the study population	Tool to measure QoL	Results
	PARALLAX trial ³⁹	2572	49% male; 72 ± 8 years	KCCQ at baseline and 12 and 24 weeks	No between-group difference in the mean change in the KCCQ (12.3 vs. 11.8; OR, 0.52; 95% CI -0.9 to 2.0)
Dapagliflozin	DELIVER ⁴⁹	6263	56% male; 71 ± 9 years	KCCQ at 8 months	Dapagliflozin improved KCCQ-TSS (+2.4; <i>P</i> < 0.05)
	PRESERVED-HF ⁵⁰	324	43% male; 69 years	KCCQ at 12 weeks	Dapagliflozin improved KCCQ-CSS (+5.8) and KCCQ-OSS (+4.5) (<i>P</i> < 0.05)
	DEFINE-HF ⁵¹	263	72% male; 62 ± 11 years	KCCQ 12 weeks	Dapagliflozin improved mean KCCQ-CSS and KCCQ-OSS at 12 weeks (4.6 and 3.7 points higher vs. placebo; <i>P</i> < 0.0001 for all)
Empagliflozin	EMPEROR-Preserved (sub-analysis) ⁵²	5988	55% male; 72 years	KCCQ at baseline and 12, 32, and 52 weeks	Empagliflozin improved KCCQ-CSS (+1.03, +1.24, and +1.50 at 12, 32, and 52 weeks, respectively; <i>P</i> < 0.01)
	EMPERIAL trial ⁴²	315	75% male; 69 ± 10 years,	KCCQ-TSS at baseline and Week 12	Empagliflozin did not improve KCCQ-TSS
Spirolactone	TOPCAT (sub-analysis) ⁵³	3445	48% male; 69 years	KCCQ and EQ-5D Visual Analogue Scale at baseline, 4–12 months, and annually after	Improvement in KCCQ in the spironolactone vs. the placebo group at 4- (1.54; <i>P</i> = 0.002), 12- (1.35; <i>P</i> = 0.02), and 36-month (1.86; <i>P</i> = 0.02) visits
Isosorbide mononitrate	NEAT-HFpEF ⁵⁴	110	43% male; 69 years	MLHFQ and KCCQ at baseline and 6 weeks	No effect between isosorbide mononitrate 120 mg vs. placebo in KCCQ (-1.91; <i>P</i> = 0.16) and MLHFQ (+1.62; <i>P</i> = 0.37)
Inhaled nebulized inorganic nitrite	INDIE-HFpEF ⁵⁵	105	44% male; 68 years	KCCQ at baseline and 4 weeks	No difference in KCCQ (62.6 vs. 61.9; <i>P</i> = 0.39)
Praliciguat	CAPACITY-HF ⁵⁶	196	56% male; 70 ± 9 years	KCCQ at baseline and 12 weeks	No difference (defined as having ≥5-point improvement from baseline) vs. placebo
Vericiguat	VITALITY-HFpEF ⁵⁷	789	51% male; 72 ± 9 years	KCCQ at baseline and 14 weeks	No difference in KCCQ (5.5 points in 15 mg/d vericiguat group, 6.5 points in the 10 mg/d vericiguat group, and 6.9 points in the placebo group)

CI, confidence interval; CSS, clinical summary score; LVEF, left ventricular ejection fraction; OR, odd ratio; OSS, overall summary score; QoL, quality of life; TSS, total summary score; years, mean age. For remaining abbreviations, refer to [Tables 1](#) and [2](#).

Cardiac devices and structural interventions

[Table 4](#) present results from randomized clinical trials evaluating the effect of non-pharmacological interventions on QoL measures, principally assessed by KCCQ and MLHFQ. Overall, the magnitude of the improvement in QoL measures with treatment vs. control was larger

and more homogeneous for studies on devices, which might also be explained by an unfeasible blinding.

For instance, in the COAPT trial, transcatheter mitral valve repair determined a 1-month mean between-group difference of 15.9 points in KCCQ-OSS which was sustained over time.⁷⁸

In most pharmacologic trials, including the more recent trials on SGLT2i, the average treatment effect on KCCQ was <5 points.

Table 4 Cardiac devices and structural interventions on heart failure affecting quality of life

	Study	Study population	Characteristics of the study population	Tool to measure QoL	Results
Cardiac resynchronization therapy	ANXIETY CHF ⁵⁸	132 HFrEF patients	71% male; 61 ± 14 years	MLHFQ at baseline and 5, 12, and 24 months	MLHFQ improved after implantation (−6.74, <i>P</i> < 0.001)
	MUSTIC ⁵⁹	58 HFrEF	77% male; 64 ± 9 years, 23% LVEF	MLHFQ at 12 and 24 weeks	MLHFQ improved after implantation (−4 vs. ±1 points, <i>P</i> < 0.001)
	MIRACLE ⁶⁰	453 HFrEF (225 vs. 228)	68% male; 64 ± 10 years, 21% LVEF	MLHFQ at 6 months	MLHFQ improved after implantation (−18 vs. −9 points, <i>P</i> < 0.001)
	MIRACLE-ICD ⁶¹	369 HFrEF (182 vs. 187)	77% male; 67 ± 9 years, 23% LVEF	MLHFQ at 6 months	MLHFQ improved after implantation (−17 vs. −11 points, <i>P</i> = 0.02)
	COMPANION ⁶²	1520	69% male; 68 years, 22% LVEF	MLHFQ at 3.6 months	MLHFQ improved after implantation (−24 and −26 vs. −9 and −12 points in placebo; <i>P</i> < 0.001)
	CARE-HF ⁶³	813	73% male; 66 years, 25% LVEF	MLHFQ and EQ-5D at 3 months	MLHFQ: −10 points (<i>P</i> < 0.001); EQ-5D: +0.8 points (<i>P</i> < 0.001)
Cardiac contractility modulation (CCM)	FIX-HF-5 ⁶⁴ (sub-group analysis)	53 HFrEF	70% male; 62 ± 1 years, 42% LVEF	MLHFQ at baseline and 6 months	MLHFQ did not significantly improve after implantation (−13.1 ± 21.0, <i>P</i> = 0.10)
Carotid baroreflex activation therapy (BAROSTIM)	BEAT-HF ⁶⁵	408 HFrEF	79% male; 63 years, 27% LVEF	MLHFQ at baseline and 6 months	MLHFQ improved after implantation (−14.1; 95%, <i>P</i> < 0.001)
Transcatheter interatrial shunt devices (IASD)	Systematic review and meta-analysis ⁶⁶	226 HF patients	44–92% male; 66–70 years	KCCQ at baseline and 12 months	KCCQ improved by 17.7 points (95% CI 10.8–24.6, <i>P</i> < 0.001)
Transcatheter mitral valve repair	COAPT ⁶⁷	614 HFrEF (302 vs. 312)	66% male; 71 ± 11 years, 31% LVEF	KCCQ and SF-36 at 1, 6, 12, and 24 months	KCCQ +15.9, 15.3, 14.5, and 12.8 at 1, 6, 12, and 24 months, respectively; SF-36 +5.3, 4.9, 4.5, and 3.6 at 1, 6, 12, and 24 months, respectively
Ventricular assist devices (VAD)	Continuous (CF) vs. pulsatile flow (PF) VAD ⁶⁸	200 (134 CF vs. 66 PF VAD)	81% (CF) and 90% (PF) male; 64 years, 17% LVEF	MLHFQ and KCCQ at 3, 12, and 24 months	MLHFQ improved by −41 and −31 in CF and PF vs. baseline at 12 months (<i>P</i> < 0.001); KCCQ-OSS improved by +38 and +32 in CF and PF at 12 months (<i>P</i> < 0.001); KCCQ-CSS improved by +37 and +29 in CF and PF vs. baseline at 12 months (<i>P</i> < 0.001)
	HeartMate II Continuous flow LVAD ⁶⁹	655 (281 BTT; 374 DT)	75% male; 50 years in BTT and 63 years in DT, 16% LVEF	MLHFQ, KCCQ-OSS, and KCCQ-CSS at 6 months in BTT and 24 months in DT	MLHFQ improved in BTT (by −28 at 6 months) and in DT (by −41 at 24 months) (<i>P</i> < 0.001); KCCQ-OSS improved in BTT (by 27 at 6 months) and in DT (by 42 at 24 months) (<i>P</i> < 0.001); KCCQ-CSS improved in BTT (by 25 at 6 months) and in DT (by 38 at 24 months) (<i>P</i> < 0.001)
Pulmonary vein isolation (PVI) in atrial fibrillation	PABA-CHF ⁷⁰	41 (PVI) vs. 40 (AVNA)	95% male in PVI and 81% male in AVNA, 60 years, 27% LVEF	MLHFQ at 6 months	MLHFQ improved by −29 vs. −7 in PVI vs. AVNA (<i>P</i> < 0.01)

AVNA, atrio-ventricular node ablation; BTT bridge to transplant; DT, destination therapy; HFrEF, heart failure with reduced ejection fraction; LVAD, left ventricular assist device. For remaining abbreviations, refer to [Tables 1–3](#).

Implantable cardioverter defibrillator and cardiac resynchronization therapy

In patients with arrhythmias and HF, implantation of a cardiac device is associated with a significant survival benefit and improvement in functional capacity, depending on the type of device. Because of technological advancements over the last two decades, there is a wide range of implantable cardiac device alternatives for a wide range of clinical conditions and indications.⁷⁹

In general, all old trials on implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy (CRT) are consistently showing an improvement in MLHFQ after implantation. More specifically, the ANXIETY-CHF study investigated heart-focused anxiety, general anxiety, depression, and QoL in patients with HF.⁵⁸

Psychological measures were assessed before and up to 2 years after the implantation of an ICD.

In this interesting report, total anxiety and related fear and attention and QoL improved significantly after device implantation. On the contrary, depression and HF-related avoidance of physical activity remained unchanged. As expected, HF-related anxiety seems to be more pronounced after defibrillator interventions and, therefore, psychological counselling in these patients is required not only to reduce anxiety but, also, to increase physical activity.

Cardiac contractility modulation

Cardiac contractility modulation (CCM), consisting of non-excitatory electrical signals delivered to the heart during the absolute refractory period, is considered safe, improves exercise tolerance but not QoL (MLHFQ) in patients with NYHA functional class III or IV, QRS duration <130 ms and LVEF $\geq 25\%$ and $\leq 45\%$.⁶⁴

Cardiac contractility modulation is delivered by a two-lead system allowing CCM therapy even in patients with atrial fibrillation,⁸⁰ and it seems to exert more favourable effects on exercise tolerance in patients with mildly reduced LVEF with an adequate safety profile with respect to more severe left ventricular function.⁸¹

Carotid baroreflex activation therapy

Baroreflex activation therapy (BAT) represents a promising therapeutic modality, offering better functional capacity, better QoL, and lower natriuretic peptide levels according to the multicentre, prospective, randomized, controlled BeAT-HF trial.⁶⁵

But, again, well-powered studies with longer follow-up and diverse populations are needed before BAT can be incorporated in the HF guidelines and, therefore, in routine clinical practice.

Pulmonary vein isolation in atrial fibrillation

A small randomized trial evaluating the effect pulmonary vein isolation vs. atrioventricular ablation with pacing in symptomatic HF patients with permanent atrial fibrillation showed an improvement in MLHFQ at 6 months.

Transcatheter interatrial shunt devices

An encouraging meta-analysis of transcatheter interatrial shunt devices for improvement in functional capacity measured by 6-min walking test and QoL (assessed by MLHFQ or KCCQ questionnaires), as well as for reductions in pulmonary capillary wedge pressure, regardless of LVEF, was recently published.⁶⁶

However, in a well-organized, randomized controlled multicentre study, atrial shunt device in 626 patients with LVEF $\geq 40\%$ offered no benefit in the total rate of HF events or in the health status.⁸²

Transcatheter mitral valve repair

Evaluation of clinical status and QoL in a HF patient with functional mitral regurgitation candidate for percutaneous mitral valve repair is of paramount importance.

The patient who fulfils all the criteria for a Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation (COAPT)-like profile has a lot better prognosis compared with the non-COAPT-like profile patient together with improved QoL at 24-month follow-up.⁸³

The criteria to be considered are absence of severe left ventricular dysfunction (LVEF < 20%), absence of severe non-reversible pulmonary hypertension, and absence of severe right ventricular dysfunction.

Furthermore, mitral valve repair might enable us to 'buy' time in candidates for heart transplantation (HTx) either listed or bridged to decision.

Interestingly, in the MitraBridge Registry, two-thirds of the MitraClip patients were free from HTx or ventricular assist device (VAD) implantation or HF hospitalization and one out of four had no more indication for HTx because of functional improvement.⁸⁴

Ventricular assist devices

In addition to survival benefits, important improvement in functional capacity and HF-related QoL is noted in the first 3 months and is maintained out to at least 24 months post-implant with ~80% of the queried patients to express their satisfaction with their consensus to have VAD therapy, at least during the first 2 years post implantation.^{85,86}

Long-term VAD-supported patients, however, had still impaired QoL and sexual function at follow-up, despite an improvement in the frequency of HF symptoms, social interactions, and independency.⁸⁷

Therefore, consultation and education of both patient and caregiver, capturing the whole spectrum of 'living with an VAD' including social interactions, driving, and sexual function, should be integrated into the pre-VAD implantation assessment and preparation to facilitate the way for further improvement in the well-being of the VAD patient.

Physical activity and exercise-based cardiac rehabilitation

In contrast with the pharmacological interventions or device implantations in HF, physical training and exercise-based cardiac rehabilitation have consistently shown very positive and undisputable effects on QoL, whatever the level of LVEF. Consequently, the 2021 ESC HF guidelines recommend physical training to improve QoL for all HF patients.⁸⁸ In HFREF, this recommendation is based on the evidence of the HF-ACTION trial, the largest trial conducted with physical training.²⁶ The more recent EXTRAMATCH 2 meta-analysis⁸⁹ confirmed the benefit independently of LVEF or the type of rehabilitation (aerobic or aerobic plus resistive).

Regarding HFpEF patients, studies are clearly less numerous but a similar beneficial effect was found. For example, the OptimEX-CLIN study⁹⁰ showed improved QoL domains in moderate continuous training compared with control [11 (95% CI, 2–19)].

Also in more fragile old patients recently discharged from HF decompensation, there is evidence of improvement in QoL by physical rehabilitation.⁹¹ Resistance training also improves QoL, although to a lesser extent generally.⁹² There is also a dose/effect relationship of physical training on QoL, although less obvious in usual aerobic exercise than in HIIT in HFpEF.⁹³ Interesting, in older overweight/obese patients with HFpEF, where both caloric restriction diet and aerobic exercise training increased pVO₂, only diet had a significant effect on QoL,⁹⁴ which was consistent with previous study showing poor acceptance of exercise training by older obese individuals⁹⁵ (Table 5).

Holistic approach

Under this category, interventions aiming at providing support that looks at the whole person are presented. In general, evidences are based on small trials and few prospectively randomized, and consequently difficult to analyse, with inconsistent findings (Table 5).

Table 5 Exercise-based cardiac rehabilitation and holistic approach interventions on heart failure affecting quality of life

	Study	Study population	Characteristics of the study population	Tool to measure QoL	Results
Exercise-based cardiac rehabilitation	HF-ACTION ²⁶	2331 HF rEF	71% male, 59 years, 24% LVEF	KCCQ at baseline and every 3 months for 12 months and annually thereafter for up to 4 years	KCCQ-OSS improved by 5.2 points in the exercise vs. 3.3 points in the control group ($P < 0.01$)
	EXTRAMATCH 2 (IPD meta-analysis) ⁹⁶	3990 HF rEF	73% male, 61 years, 27% LVEF	MLHFQ at baseline and 12 months	MLHFQ improved significantly (mean score -5.8 points, 95% CI: -9.2 to -2.4 points)
	OptimEX-CLIN ⁹⁰	180 HF pEF	43% male, 67 years, $>50\%$ LVEF	KCCQ at baseline, 3 and 12 months	KCCQ did not significantly differ between groups after 3 months of exercise intervention. At 12 months, the QoL improved in moderate continuous training vs. control (11, 95% CI 2–19)
	REHAB HF study ⁹¹	349 HF rEF	48% male, 73 years, $>45\%$ LVEF in 93%	KCCQ at baseline and 3 months	KCCQ improved: 69 vs. 62 ($P = 0.007$)
	Exercise and caloric restriction ⁹⁴	100 obese	67 ± 5 years, BMI 39 ± 5 , 60% LVEF	KCCQ at 20 weeks	Diet (-7 points, $P < 0.001$) but not exercise (-2 points) improved KCCQ
Holistic approach Patient's education and self-management	Education on drug adherence ⁹⁷	82	57% male, 60 ± 5 years	MLHFQ at 12 months	No benefit on QoL
	Systematic IPD meta-analysis ⁹⁸	5624 (20 studies)	56% male, 69 years	KCCQ and MLHFQ at 6 and 12 months,	No benefit on QoL
	Systematic review ⁹⁹	7 studies	1178	MLHFQ at 12 months	Only one study documented improvement in QoL
Motivational interviewing (MI)	Systematic review and meta-analysis ¹⁰⁰	1214 (9 studies)	65% males, 58–78 years	1–16 months of follow-up	MI improved self-care confidence and self-care management and self-care maintenance
Psychological interventions	Systematic review ²⁰	757 (9 studies)	40–68 years	KCCQ and MLHFQ with 3–12 months of follow-up	Four studies reported improvement in QoL
Supportive care	Systematic review and meta-analysis ¹⁰¹	867 (10 studies)	33–79 years	MLHFQ with 12 weeks to 12 months of follow-up	No benefit on QoL

CBT, cognitive behavioural therapy; CRT-P/CRT-D, cardiac resynchronization therapy with pacing/defibrillator; IPD, individual patient data. For remaining abbreviations, refer to [Tables 1–4](#).

Self-care can be defined as a process of health promoting and preventive practices with patients and their relatives' engagement. Heart failure education is considered as a part of self-care process, focused on symptoms and signs, medical treatment, and behavioural changes. Randomized controlled studies of HF programmes that include self-care demonstrate improved outcomes and hospital readmission due to HF worsening but non-consistent data on QoL.^{97–99}

Motivational Interviewing is a widely adopted counselling intervention which elicits and strengthens motivation to change and has been used as an effective strategy for improving HF self-care behaviours (i.e. self-care maintenance, management, physical activity, and knowledge). A systemic review showed that this strategy reduces the burden

of HF physical symptoms, especially when the intervention is performed on both patients and caregivers as a dyad.^{100,102}

Psychological intervention for patient's empowerment refers to a process that enables people to have greater influence over their own health by gaining greater control of what they themselves define as important. It refers to well-informed patients taking responsibility for their own health, to as great an extent as possible, and the expected benefits of improved QoL. In a systemic review of nine studies, four have found to improve outcomes including QoL, mental health (depression, anxiety) and adherence.¹⁰³

Supportive care is a multidisciplinary holistic care provided in the patient and his family, from the time of diagnosis along with treatment

aiming to prolong life expectancy and improve QoL and into end-of-life care. It is composed of four components: communication and decision-making, education, symptom management, and psychological and spiritual issues, initially provided to patients with cancer. In the meta-synthesis of Kyriakou et al.^{101,104} supportive care showed a not significant effect on QoL but a positive effect of the interventions on the physical and emotional dimensions.

Mobile health

Mobile health (mHealth), broadly defined as the use of mobile computing and wireless communication technologies in health care, offers scalable and affordable opportunities for expanding delivery of care services outside of hospital settings to assist patients with self-monitoring and management of HF symptoms.¹⁰⁵

In a systematic review on 18 studies on mHealth, QoL was investigated in 11: in only 4 that contained telemonitoring combined with telephone support, QoL improved.¹⁰⁶

There was insufficient data on the cost-effectiveness of mHealth interventions to do meaningful analysis.

Gaps in knowledge and conclusions

A QoL instrument may be useful for many different purposes, for example, for long-term follow-up of individual patients or in the evaluation of treatments designed to improve QoL. But we can identify at least two gaps in knowledge.

What is the minimal clinical important difference for quality of life in heart failure?

It is critical to ascertain the magnitude of within-patient change that is meaningful to patients.¹⁰⁷

As a tool (such as QoL questionnaire) becomes more common to assess treatment efficacy, it is critical to leverage clinically important thresholds of change and to analyse the results to provide more clinically relevant ways of understanding the benefits of treatment. In this aspect, the definition of minimal clinical important difference, i.e. the level that is meaningful to patients, is crucial. Both KCCQ and MLHFQ were designed and validated as HF-specific tools to evaluate health status. While population-level mean differences between the active and control groups can be compared in a research setting, understanding how these differences impact individual patient QoL is more complicated.

To do this, it is necessary to identify groups of patients who experience small, moderate, or large improvements or deteriorations. Efforts to understand the within-patient change have created estimates close to the original thresholds of 5, 10, and 15–20 points that indicate small to moderate (but clinically important), moderate to large, and large to very large clinical changes, respectively.

Trials can not only report the mean differences in scores between groups but also the proportion of participants in each arm who have changes of different levels. This is achieved by responder analysis and reporting the proportions of patients who achieve benefits of various levels, e.g. 5-, 10-, and 15-point improvement in KCCQ score. These numbers can be converted to the total number-needed-to-treat (NNT) for one patient to experience an important change in health status, e.g. patients treated with dapagliflozin had more patients than placebo who experienced 5- (58.3% vs. 50.9%), 10- (54.5% vs. 47.6%) and 15-point (54.0% vs. 48.2%) improvement in KCCQ-TSS, corresponding to NNTs of 14, 15, and 18, respectively.⁴⁰

Such information may be valuable for clinicians and patients to understand the treatment benefits. These are potential ways to leverage health status outcomes to provide intuitive ways to quantify and understand the benefits of treatments.

Do we need a new quality of life measurement tool in heart failure?

Quality of life has many characteristics, including physical exercise ability, congested symptoms, psychological effects of disease, social functioning, cognitive impairment, sleep quality, and anxiety.

However, most treatments are highly specific in improving a specific function, such as haemodynamic or muscular, and hence having effects largely focused on one particular sign or symptom.

Perhaps current scoring systems for general QoL are too wide to detect changes caused by treatment interventions.

Thus, instead of searching for the holy grail of a single QoL tool, we may be better off breaking it down into pieces and developing tools, more sensitive to specific disease components impacting on QoL.

A second consideration is whether a QoL instrument should be more personalized and considering differences in QoL between young persons with minor sickness vs. extremely elderly people with various comorbidities and restricted exercise capacity.

An alternate strategy, which has not been created, is to build a QoL score that crosses severe disease to small disease within an individual patient's expectations, so that scores are benchmarked (e.g. on a 0–100 score) relevant to their expectations.

It is for these reasons that the Heart Failure Association is developing a new score for QoL in HF, sensitive to mechanism-specific interventions and tailored to be sensitive to changes within individual patients.

Authorship statement

All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published.

Conflict of interest: S.A. reports payment or honoraria for lectures: AstraZeneca and Genesis Pharma. P.A. reports consulting fees from Schiller, payment or honoraria for lectures, presentations from CPX International, and Advisory Board for AstraZeneca. J.B. reports consulting fee: Abbott, Adrenomed, Amgen, Applied Therapeutics, Array, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CVRx, G3 Pharma, Impulse Dynamics, Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, Novo Nordisk, Relypsa, Roche, Sequana Medical, and Vifor and speaker fees: Novartis, Boehringer Ingelheim-Lilly, AstraZeneca, and Janssen. A.J.S.C. declares having received fees from AstraZeneca, Bayer, Boehringer Ingelheim, Edwards, Menarini, Novartis, Servier, Vifor, Abbott, Actimed, Arena, Cardiac Dimensions, Corvia, CVRx, Enopace, ESN Cleer, Faraday, Impulse Dynamics, Respicardia, and Viatrix. A.C.-S. reports consulting fee from Novartis, Bayer, AstraZeneca, Boehringer, Sanofi, and Vifor. W.D. reports consulting and speaker fees from Aimediq, Bayer, Boehringer Ingelheim, Lilly, Medtronic, and Vifor Pharma and research support from the EU (Horizon2020), German Ministry of Education and Research, German Centre for Cardiovascular Research, and Vifor Pharma (none of the mentioned is related to this manuscript). P.P.F. reports consulting and speaker fees: Sanofi, Boehringer, AstraZeneca, Novartis, Bruno Farma. G.F. reports lecture fees from Bayer, Boehringer Ingelheim, Servier, Novartis, trial committee membership fees from Bayer, Boehringer Ingelheim, Servier, Impulse Dynamics, Vifor, Medtronic and consulting fees from Cardior, Novo Nordisk; Research Grants from the European Union. C.S.P.L. is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Bayer and Roche Diagnostics; has served as consultant or on the Advisory Board/Steering Committee/Executive Committee for Actelion, Alleviant Medical, Allysta Pharma, Amgen, AnaCardio AB, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim,

Boston Scientific, Cytokinetics, Darma Inc., EchoNous Inc., Eli Lilly, Impulse Dynamics, Intellia Therapeutics, Ionis Pharmaceutical, Janssen Research & Development LLC, MedScape/WebMD Global LLC, Merck, Novartis, Novo Nordisk, ProSciento Inc., Radcliffe Group Ltd., Redcardio Inc., ReCor Medical, Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics, and Us2.ai; and serves as co-founder and non-executive director of Us2.ai. L.H.L. is supported by Karolinska Institutet, the Swedish Research Council (grant 523–2014–2336), the Swedish Heart Lung Foundation (grants 20150557 and 20190310), and the Stockholm County Council (grants 20170112, 20190525); grants: AstraZeneca, Vifor, Boston Scientific, Boehringer Ingelheim, Novartis, and MSD; consulting: Vifor, AstraZeneca, Bayer, Pharmacosmos, MSD, MedScape, Sanofi, Lexicon, MyoKardia, Boehringer Ingelheim, Servier, Edwards Lifesciences, and Alleviant; speaker's honoraria: Abbott, OrionPharma, MedScape, Radcliffe, AstraZeneca, Novartis, Boehringer Ingelheim, and Bayer; patent: AnaCardio; and stock ownership: AnaCardio. M.M. reports participation on a Data Safety Monitoring Board from Amgen, LivaNova, and Vifor Pharma as member of Executive or Data Monitoring Committees of sponsored clinical trials and from AstraZeneca, Bayer, Boehringer Ingelheim, Edwards Lifesciences for participation to Advisory Boards. S.P. reports payment or honoraria for lectures: Novo Nordisk and Merck Serono and support for attending meetings: Dompé. M.P. reports receipt of honoraria or consultation fees from AstraZeneca, Boehringer and Ingelheim, CHF solution, Menarini, Novartis, Novo Nordisk, Servier, and Vifor. G.R. reports support for attending meetings and/or travel from AstraZeneca, Boehringer Ingelheim, and Servier. G.S. reports grants from Vifor Pharma, Novartis, Boehringer Ingelheim, Boston Scientific, AstraZeneca, Pharmacosmos, Merck, Bayer, Cytokinetics, and Horizon 2022 funding; consulting fee from TEVA, MIUR (Ministero dell'Istruzione, Università e Ricerca), Medical Education Global Solutions, Atheneum, Genesis, Vifor Pharma, Agence Recherche (ANR), and TEVA; payment of honoraria from Servier, Roche, Cytokinetics, Translational Medicine Academy Foundation (TMA), Medtronic, Medical Education Global Solutions, Dynamicom Education, AstraZeneca, Vifor Pharma, and Novartis; and Advisory Board: AstraZeneca, Edwards, Uppsala Clinical Research Center (UCR), Vifor, and Servier. P.S. reports receipt of honoraria: Servier, AstraZeneca, Menarini, Boehringer Ingelheim, Novartis, and Roche Diagnostics. C.G.T. reports receipt of honoraria or consultation fees: Vivalyfe, Univers Formazione, Solaris, Myocardial Solutions, Summeet, AstraZeneca, and Medtronic; funding from Amgen and MSD; and two grants from the Italian Ministry of Health (PNRR-MAD-2022-12376632 and RF-2016-02362988) and is listed as an inventor of two patents related to HF. All the other authors report no conflict of interest.

References

- Lewis EF, Johnson PA, Johnson W, Collins C, Griffin L, Stevenson LW. Preferences for quality of life or survival expressed by patients with heart failure. *J Heart Lung Transplant* 2001;**20**:1016–1024.
- Del Buono MG, Arena R, Borlaug BA, Carbone S, Canada JM, Kirkman DL, et al. Exercise intolerance in patients with heart failure. *J Am Coll Cardiol* 2019;**73**:2209–2225.
- Freedland KE, Rich MW, Carney RM. Improving quality of life in heart failure. *Curr Cardiol Rep* 2021;**23**:159.
- Taylor CJ, Roalfe AK, Iles R, Hobbs FDR. Ten-year prognosis of heart failure in the community: follow-up data from the Echocardiographic Heart of England Screening (ECHOES) study. *Eur J Heart Fail* 2012;**14**:176–184.
- Stewart S, Ekman I, Ekman T, Odén A, Rosengren A. Population impact of heart failure and the most common forms of cancer: a study of 1 162 309 hospital cases in Sweden (1988 to 2004). *Circ Cardiovasc Qual Outcomes* 2010;**3**:573–580.
- Heo S, Lennie TA, Okoli C, Moser DK. Quality of life in patients with heart failure: ask the patients. *Heart Lung* 2009;**38**:100–108.
- Kraai IH, Vermeulen KM, Luttik MLA, Hoekstra T, Jaarsma T, Hillege HL. Preferences of heart failure patients in daily clinical practice: quality of life or longevity? *Eur J Heart Fail* 2013;**15**:1113–1121.
- Moons P, Norekvål TM, Arbelo E, Borregaard B, Casadei B, Cosyns B, et al. Placing patient-reported outcomes at the centre of cardiovascular clinical practice: implications for quality of care and management. *Eur Heart J* 2023;**44**:3405–3422.
- Coelho R, Ramos S, Prata J, Bettencourt P, Ferreira A, Cerqueira-Gomes M. Heart failure and health related quality of life. *Clin Pract Epidemiol Ment Health* 2005;**1**:19.
- Chipper H, Clinch JJ, Olweny CLM. Quality of life studies: definitions and conceptual issues. In: Spilker B (ed.), *Quality of life and pharmacoeconomics in clinical trials*. Philadelphia: Lippincott-Raven Publishers; 1996. p11–23.
- Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. *J Am Coll Cardiol* 2000;**35**:1245–1255.
- Bilbao A, Escobar A, García-Pérez L, Navarro G, Quirós R. The Minnesota Living with Heart Failure Questionnaire: comparison of different factor structures. *Health Qual Life Outcomes* 2016;**14**:23.
- Mannheimer B, Andersson B, Carlsson L, Währborg P. The validation of a new quality of life questionnaire for patients with congestive heart failure—an extension of the Cardiac Health Profile. *Scand Cardiovasc J* 2007;**41**:235–241.
- Khajavi A, Moshki M, Minaee S, Vakilian F, Montazeri A, Hashemzadeh H. Chronic heart failure health-related quality of life questionnaire (CHFQOLQ-20): development and psychometric properties. *BMC Cardiovasc Disord* 2023;**23**:165.
- Dunderdale K, Thompson DR, Beer SF, Furze G, Miles JNV. Development and validation of a patient-centered health-related quality-of-life measure: the Chronic Heart Failure Assessment Tool. *J Cardiovasc Nurs* 2008;**23**:364–370.
- O'Leary CJ. The Left Ventricular Dysfunction Questionnaire (LVD-36): reliability, validity, and responsiveness. *Heart* 2000;**83**:634–640.
- Dunderdale K, Thompson DR, Miles JNV, Beer SF, Furze G. Quality-of-life measurement in chronic heart failure: do we take account of the patient perspective? *Eur J Heart Fail* 2005;**7**:572–582.
- Balestroni G, Bertolotti G. EuroQol-5D (EQ-5D): an instrument for measuring quality of life. *Monaldi Arch Chest Dis* 2012;**78**:155–159.
- Ware JE, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection. *Med Care* 1992;**30**:473–483.
- Helal SI, Lee G, Evans C, Grealish A. The efficacy of psychological interventions on health-related quality of life for patients with heart failure and depression: a systematic review. *J Cardiovasc Nurs* 2022;**37**:134–145.
- Kelkar AA, Spertus J, Pang P, Pierson RF, Cody RJ, Pina IL, et al. Utility of patient-reported outcome instruments in heart failure. *JACC Heart Fail* 2016;**4**:165–175.
- U.S. Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health. Guidance for Industry, Tool Developers, and Food and Drug Administration Staff—Qualification of medical device development tools. [Internet]. Available from: <https://www.fda.gov/media/87134/download> (last accessed 10 January 2023).
- Spertus JA, Jones PG. Development and validation of a short version of the Kansas City Cardiomyopathy Questionnaire. *Circ Cardiovasc Qual Outcomes* 2015;**8**:469–476.
- Spertus J, Peterson E, Conard MW, Heidenreich PA, Krumholz HM, Jones P, et al. Monitoring clinical changes in patients with heart failure: a comparison of methods. *Am Heart J* 2005;**150**:707–715.
- Hawwa N, Vest AR, Kumar R, Lahoud R, Young JB, Wu Y, et al. Comparison between the Kansas City Cardiomyopathy Questionnaire and New York Heart Association in assessing functional capacity and clinical outcomes. *J Card Fail* 2017;**23**:280–285.
- Flynn KE, Piña IL, Whellan DJ, Lin L, Blumenthal JA, Ellis SJ, et al. Effects of exercise training on health status in patients with chronic heart failure: hF-ACTION randomized controlled trial. *JAMA* 2009;**301**:1451–1459.
- Arena R, Humphrey R, Peberdy MA. Relationship between the Minnesota Living with Heart Failure Questionnaire and key ventilatory expired gas measures during exercise testing in patients with heart failure. *J Cardiopulm Rehabil* 2002;**22**:273–277.
- Hole T, Grundtvig M, Gullestad L, Flønæs B, Westheim A. Improved quality of life in Norwegian heart failure patients after follow-up in outpatient heart failure clinics: results from the Norwegian Heart Failure Registry. *Eur J Heart Fail* 2010;**12**:1247–1252.
- Moser DK, Yamokoski L, Sun JL, Conway GA, Hartman KA, Graziano JA, et al. Improvement in health-related quality of life after hospitalization predicts event-free survival in patients with advanced heart failure. *J Card Fail* 2009;**15**:763–769.
- Napier R, McNulty SE, Eton DT, Redfield MM, AbouEzzeddine O, Dunlay SM. Comparing measures to assess health-related quality of life in heart failure with preserved ejection fraction. *JACC Heart Fail* 2018;**6**:552–560.
- Yee D, Novak E, Platts A, Nassif ME, LaRue SJ, Vader JM. Comparison of the Kansas City Cardiomyopathy Questionnaire and Minnesota Living with Heart Failure Questionnaire in predicting heart failure outcomes. *Am J Cardiol* 2019;**123**:807–812.
- Greene SJ, Butler J, Spertus JA, Hellkamp AS, Vaduganathan M, DeVore AD, et al. Comparison of New York Heart Association class and patient-reported outcomes for heart failure with reduced ejection fraction. *JAMA Cardiol* 2021;**6**:522–531.

33. Guyatt GH, Nogradi S, Halcrow S, Singer J, Sullivan MJJ, Fallen EL. Development and testing of a new measure of health status for clinical trials in heart failure. *J Gen Intern Med* 1989;**4**:101–107.
34. Wiklund I, Lindvall K, Swedberg K, Zupkis RV. Self-assessment of quality of life in severe heart failure: an instrument for clinical use. *Scand J Psychol* 1987;**28**:220–225.
35. Herdman M, Gudex C, Lloyd A, Janssen MF, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). *Qual Life Res* 2011;**20**:1727–1736.
36. Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R, Ferdinand K, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. *N Engl J Med* 2004;**351**:2049–2057.
37. Riccioni G, Masciocco L, Benvenuto A, Saracino P, De Viti D, Massari F, et al. Ivabradine improves quality of life in subjects with chronic heart failure compared to treatment with β -blockers: results of a multicentric observational APULIA study. *Pharmacology* 2013;**92**:276–280.
38. Ekman I, Chassany O, Komajda M, Böhm M, Borer JS, Ford I, et al. Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. *Eur Heart J* 2011;**32**:2395–2404.
39. Pieske B, Wachter R, Shah SJ, Baldrige A, Szezoedy P, Ibram G, et al. Effect of sacubitril/valsartan vs standard medical therapies on plasma NT-proBNP concentration and submaximal exercise capacity in patients with heart failure and preserved ejection fraction: the PARALLAX randomized clinical trial. *JAMA* 2021;**326**:1919–1929.
40. Kosiborod MN, Jhund PS, Docherty KF, Diez M, Petrie MC, Verma S, et al. Effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial. *Circulation* 2020;**141**:90–99.
41. Butler J, Anker SD, Filippatos G, Khan MS, Ferreira JP, Pocock SJ, et al. Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial. *Eur Heart J* 2021;**42**:1203–1212.
42. Abraham WT, Lindenfeld J, Ponikowski P, Agostoni P, Butler J, Desai AS, et al. Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. *Eur Heart J* 2021;**42**:700–710.
43. Kosiborod MN, Angermann CE, Collins SP, Teerlink JR, Ponikowski P, Biegus J, et al. Effects of empagliflozin on symptoms, physical limitations, and quality of life in patients hospitalized for acute heart failure: results from the EMPULSE trial. *Circulation* 2022;**146**:279–288.
44. Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. *N Engl J Med* 2021;**384**:117–128.
45. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. *N Engl J Med* 2009;**361**:2436–2448.
46. Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, et al. Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure. *N Engl J Med* 2021;**384**:105–116.
47. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, et al. Irbesartan in patients with heart failure and preserved ejection fraction. *N Engl J Med* 2008;**359**:2456–2467.
48. Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. *N Engl J Med* 2019;**381**:1609–1620.
49. Solomon SD, McMurray JJV, Claggett B, De Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. *N Engl J Med* 2022;**387**:1089–1098.
50. Nassif ME, Windsor SL, Borlaug BA, Kitzman DW, Shah SJ, Tang F, et al. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. *Nat Med* 2021;**27**:1954–1960.
51. Nassif ME, Windsor SL, Tang F, Khariton Y, Husain M, Inzucchi SE, et al. Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF trial. *Circulation* 2019;**140**:1463–1476.
52. Butler J, Filippatos G, Jamal Siddiqi T, Brueckmann M, Böhm M, Chopra VK, et al. Empagliflozin, health status, and quality of life in patients with heart failure and preserved ejection fraction: the EMPEROR-Preserved trial. *Circulation* 2022;**145**:184–193.
53. Lewis EF, Kim HY, Claggett B, Spertus J, Heitner JF, Assmann SF, et al. Impact of spironolactone on longitudinal changes in health-related quality of life in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. *Circ Heart Fail* 2016;**9**:e001937.
54. Redfield MM, Anstrom KJ, Levine JA, Koepp GA, Borlaug BA, Chen HH, et al. Isosorbide mononitrate in heart failure with preserved ejection fraction. *N Engl J Med* 2015;**373**:2314–2324.
55. Borlaug BA, Anstrom KJ, Lewis GD, Shah SJ, Levine JA, Koepp GA, et al. Effect of inorganic nitrite vs placebo on exercise capacity among patients with heart failure with preserved ejection fraction: the INDIE-HFpEF randomized clinical trial. *JAMA* 2018;**320**:1764–1773.
56. Udelson JE, Lewis GD, Shah SJ, Zile MR, Redfield MM, Burnett J, et al. Effect of praliquat on peak rate of oxygen consumption in patients with heart failure with preserved ejection fraction: the CAPACITY HFpEF randomized clinical trial. *JAMA* 2020;**324**:1522–1531.
57. Armstrong PW, Lam CSP, Anstrom KJ, Ezekowitz J, Hernandez AF, O'Connor CM, et al. Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: the VITALITY-HFpEF randomized clinical trial. *JAMA* 2020;**324**:1512–1521.
58. Kindermann I, Wedegärtner SM, Bernhard B, Ukena J, Lenski D, Karch J, et al. Changes in quality of life, depression, general anxiety, and heart-focused anxiety after defibrillator implantation. *ESC Heart Fail* 2021;**8**:2502–2512.
59. Cazeau S, Leclercq C, Lavergne T, Walker S, Varma C, Linde C, et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. *N Engl J Med* 2001;**344**:873–880.
60. Young JB. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD trial. *JAMA* 2003;**289**:2685–2694.
61. Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, et al. Cardiac resynchronization in chronic heart failure. *N Engl J Med* 2002;**346**:1845–1853.
62. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. *N Engl J Med* 2004;**350**:2140–2150.
63. Cleland JGF, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al. The CARE-HF study (Cardiac Resynchronization in Heart Failure study): rationale, design and end-points. *Eur J Heart Fail* 2001;**3**:481–489.
64. Abraham WT, Kuck KH, Goldsmith RL, Lindenfeld J, Reddy VY, Carson PE, et al. A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation. *JACC Heart Fail* 2018;**6**:874–883.
65. Zile MR, Lindenfeld J, Weaver FA, Zannad F, Galle E, Rogers T, et al. Baroreflex activation therapy in patients with heart failure with reduced ejection fraction. *J Am Coll Cardiol* 2020;**76**:1–13.
66. Lauder L, Pereira TV, Degenhardt MC, Ewen S, Kulenthiran S, Coats AJS, et al. Feasibility and efficacy of transcatheter interatrial shunt devices for chronic heart failure: a systematic review and meta-analysis. *Eur J Heart Fail* 2021;**23**:1960–1970.
67. Stone GW, Lindenfeld J, Abraham WT, Kar S, Lim DS, Mishell JM, et al. Transcatheter mitral-valve repair in patients with heart failure. *N Engl J Med* 2018;**379**:2307–2318.
68. Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. *N Engl J Med* 2009;**361**:2241–2251.
69. Pagani FD, Miller LW, Russell SD, Aaronson KD, John R, Boyle AJ, et al. Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device. *J Am Coll Cardiol* 2009;**54**:312–321.
70. Khan MN, Jaïs P, Cummings J, Di Biase L, Sanders P, Martin DO, et al. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. *N Engl J Med* 2008;**359**:1778–1785.
71. von Haehling S, Arzt M, Doehner W, Edelmann F, Evertz R, Ebner N, et al. Improving exercise capacity and quality of life using non-invasive heart failure treatments: evidence from clinical trials. *Eur J Heart Fail* 2021;**23**:92–113.
72. Piepoli MF, Hussain RI, Comin-Colet J, Dosantos R, Ferber P, Jaarsma T, et al. OUTSTEP-HF: randomised controlled trial comparing short-term effects of sacubitril/valsartan versus enalapril on daily physical activity in patients with chronic heart failure with reduced ejection fraction. *Eur J Heart Fail* 2021;**23**:127–135.
73. Halle M, Schöbel C, Winzer EB, Bernhardt P, Mueller S, Sieder C, et al. A randomized clinical trial on the short-term effects of 12-week sacubitril/valsartan vs. enalapril on peak oxygen consumption in patients with heart failure with reduced ejection fraction: results from the ACTIVITY-HF study. *Eur J Heart Fail* 2021;**23**:2073–2082.
74. Garcia RA, Benton MC, Spertus JA. Patient-reported outcomes in patients with cardiomyopathy. *Curr Cardiol Rep* 2021;**23**:91.
75. Chandra A, Vaduganathan M, Lewis EF, Claggett BL, Rizkala AR, Wang W, et al. Health-related quality of life in heart failure with preserved ejection fraction. *JACC Heart Fail* 2019;**7**:862–874.
76. Packer M, Butler J, Zannad F, Filippatos G, Ferreira JP, Pocock SJ, et al. Effect of empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction: EMPEROR-Preserved trial. *Circulation* 2021;**144**:1284–1294.
77. Omar W, Pandey A, Haykowsky MJ, Berry JD, Lavie CJ. The evolving role of cardiorespiratory fitness and exercise in prevention and management of heart failure. *Curr Heart Fail Rep* 2018;**15**:75–80.

78. Arnold SV, Chinnakondepalli KM, Spertus JA, Magnuson EA, Baron SJ, Kar S, et al. Health status after transcatheter mitral-valve repair in heart failure and secondary mitral regurgitation. *J Am Coll Cardiol* 2019;**73**:2123–2132.
79. Lindenfeld J, Feldman AM, Saxon L, Boehmer J, Carson P, Ghali JK, et al. Effects of cardiac resynchronization therapy with or without a defibrillator on survival and hospitalizations in patients with New York Heart Association class IV heart failure. *Circulation* 2007;**115**:204–212.
80. Wiegand P, Chan R, Jost C, Saville BR, Parise H, Prutchi D, et al. Safety, performance, and efficacy of cardiac contractility modulation delivered by the 2-lead optimizer smart system: the FIX-HF-5C2 study. *Circ Heart Fail* 2020;**13**:e006512.
81. Tschöpe C, Butler J, Farmakis D, Morley D, Rao I, Filippatos G. Clinical effects of cardiac contractility modulation in heart failure with mildly reduced systolic function. *ESC Heart Fail* 2020;**7**:3531–3535.
82. Shah SJ, Borlaug BA, Chung ES, Cutlip DE, Debonnaire P, Fail PS, et al. Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial. *Lancet* 2022;**399**:1130–1140.
83. Adamo M, Fiorelli F, Melica B, D'Ortona R, Lupi L, Giannini C, et al. COAPT-like profile predicts long-term outcomes in patients with secondary mitral regurgitation undergoing MitraClip implantation. *JACC Cardiovasc Interv* 2021;**14**:15–25.
84. Godino C, Munafò A, Scotti A, Estévez-Loureiro R, Portolés Hernández A, Arzamendi D, et al. MitraClip in secondary mitral regurgitation as a bridge to heart transplantation: 1-year outcomes from the International MitraBridge Registry. *J Heart Lung Transplant* 2020;**39**:1353–1362.
85. Mehra MR, Goldstein DJ, Cleveland JC, Cowger JA, Hall S, Salerno CT, et al. Five-year outcomes in patients with fully magnetically levitated vs axial-flow left ventricular assist devices in the MOMENTUM 3 randomized trial. *JAMA* 2022;**328**:1233–1242.
86. Rogers JG, Aaronson KD, Boyle AJ, Russell SD, Milano CA, Pagani FD, et al. Continuous flow left ventricular assist device improves functional capacity and quality of life of advanced heart failure patients. *J Am Coll Cardiol* 2010;**55**:1826–1834.
87. Itzhaki Ben Zadok O, Ben-Avraham B, Jaarsma T, Shaul A, Hammer Y, Barac YD, et al. Health-related quality of life in left ventricular assist device-supported patients. *ESC Heart Fail* 2021;**8**:2036–2044.
88. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumhach A, Böhm M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J* 2021;**42**:3599–3726.
89. Taylor RS, Walker S, Smart NA, Piepoli MF, Warren FC, Ciani O, et al. Impact of exercise rehabilitation on exercise capacity and quality-of-life in heart failure. *J Am Coll Cardiol* 2019;**73**:1430–1443.
90. Mueller S, Winzer EB, Duvinage A, Gevaert AB, Edelmann F, Haller B, et al. Effect of high-intensity interval training, moderate continuous training, or guideline-based physical activity advice on peak oxygen consumption in patients with heart failure with preserved ejection fraction: a randomized clinical trial. *JAMA* 2021;**325**:542–551.
91. Kitzman DW, Whellan DJ, Duncan P, Pastva AM, Mentz RJ, Reeves GR, et al. Physical rehabilitation for older patients hospitalized for heart failure. *N Engl J Med* 2021;**385**:203–216.
92. Giuliano C, Karahalios A, Neil C, Allen J, Levinger I. The effects of resistance training on muscle strength, quality of life and aerobic capacity in patients with chronic heart failure—a meta-analysis. *Int J Cardiol* 2017;**227**:413–423.
93. Bobenko A, Bartels I, Münch M, Trippel T, Lindhorst R, Nolte K, et al. Amount or intensity? Potential targets of exercise interventions in patients with heart failure with preserved ejection fraction: amount or intensity? Potential targets of exercise interventions in patients with heart failure with preserved ejection fraction. *ESC Heart Fail* 2018;**5**:53–62.
94. Kitzman DW, Brubaker P, Morgan T, Haykowsky M, Hundley G, Kraus WE, et al. Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: a randomized clinical trial. *JAMA* 2016;**315**:36–46.
95. Villareal DT, Chode S, Parimi N, Sinacore DR, Hilton T, Armamento-Villareal R, et al. Weight loss, exercise, or both and physical function in obese older adults. *N Engl J Med* 2011;**364**:1218–1229.
96. Taylor RS, Walker S, Ciani O, Warren F, Smart NA, Piepoli M, et al. Exercise-based cardiac rehabilitation for chronic heart failure: the EXTRAMATCH II individual participant data meta-analysis. *Health Technol Assess* 2019;**23**:1–98.
97. Wu JR, Corley DJ, Lennie TA, Moser DK. Effect of a medication-taking behavior feedback theory-based intervention on outcomes in patients with heart failure. *J Card Fail* 2012;**18**:1–9.
98. Jonkman NH, Westland H, Groenewold RHH, Ågren S, Anguita M, Blue L, et al. What are effective program characteristics of self-management interventions in patients with heart failure? An individual patient data meta-analysis. *J Card Fail* 2016;**22**:861–871.
99. Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet]. York (UK): Centre for Reviews and Dissemination (UK); 1995-. The effectiveness of patient-centered self-care education for adults with heart failure on knowledge, self-care behaviors, quality of life, and readmissions: a systematic review. 2014. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK247063>.
100. Ghizzardi G, Arrighoni C, Dellafiore F, Vellone E, Caruso R. Efficacy of motivational interviewing on enhancing self-care behaviors among patients with chronic heart failure: a systematic review and meta-analysis of randomized controlled trials. *Heart Fail Rev* 2022;**27**:1029–1041.
101. Kyriakou M, Middleton N, Ktisti S, Philippou K, Lambrinou E. Supportive care interventions to promote health-related quality of life in patients living with heart failure: a systematic review and meta-analysis. *Heart Lung Circ* 2020;**29**:1633–1647.
102. Vellone E, Rebora P, Ausili D, Zeffiro V, Pucciarelli G, Caggianielli G, et al. Motivational interviewing to improve self-care in heart failure patients (MOTIVATE-HF): a randomized controlled trial. *ESC Heart Fail* 2020;**7**:1309–1318.
103. Okediji PT, Salako O, Fatiregun OO. Pattern and predictors of unmet supportive care needs in cancer patients. *Cureus* 2017;**9**:e1234.
104. Kyriakou M, Samara A, Philippou K, Lakatamitou I, Lambrinou E. A qualitative meta-synthesis of patients with heart failure perceived needs. *Rev Cardiovasc Med* 2021;**22**:853–864.
105. Wathne H, Morken IM, Storm M, Husebø AML. Designing a future eHealth service for posthospitalization self-management support in long-term illness: qualitative interview study. *JMIR Hum Factors* 2023;**10**:e39391.
106. Morken IM, Storm M, Søreide JA, Urstad KH, Karlsen B, Husebø AML. Posthospitalization follow-up of patients with heart failure using eHealth solutions: restricted systematic review. *J Med Internet Res* 2022;**24**:e32946.
107. FDA. Treatment for heart failure: endpoints for drug development. Guid Ind 2019. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/treatment-heart-failure-endpoints-drug-development-guidance-industry> (Accessed April 12, 2022).